↓ Skip to main content

Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma

Overview of attention for article published in Journal for Immunotherapy of Cancer, September 2019
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (85th percentile)
  • Good Attention Score compared to outputs of the same age and source (73rd percentile)

Mentioned by

twitter
23 X users
patent
1 patent

Citations

dimensions_citation
104 Dimensions

Readers on

mendeley
78 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma
Published in
Journal for Immunotherapy of Cancer, September 2019
DOI 10.1186/s40425-019-0722-x
Pubmed ID
Authors

Mouhammed Amir Habra, Bettzy Stephen, Matthew Campbell, Kenneth Hess, Coya Tapia, Mingxuan Xu, Jordi Rodon Ahnert, Camilo Jimenez, Jeffrey E. Lee, Nancy D. Perrier, Russell R. Boraddus, Shubham Pant, Vivek Subbiah, David S. Hong, Abdulrazzak Zarifa, Siqing Fu, Daniel D. Karp, Funda Meric-Bernstam, Aung Naing

X Demographics

X Demographics

The data shown below were collected from the profiles of 23 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 78 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 78 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 12 15%
Other 10 13%
Student > Ph. D. Student 8 10%
Researcher 6 8%
Student > Doctoral Student 5 6%
Other 15 19%
Unknown 22 28%
Readers by discipline Count As %
Medicine and Dentistry 33 42%
Biochemistry, Genetics and Molecular Biology 7 9%
Agricultural and Biological Sciences 5 6%
Pharmacology, Toxicology and Pharmaceutical Science 2 3%
Nursing and Health Professions 2 3%
Other 5 6%
Unknown 24 31%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 14. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 October 2023.
All research outputs
#2,555,509
of 25,564,614 outputs
Outputs from Journal for Immunotherapy of Cancer
#696
of 3,460 outputs
Outputs of similar age
#51,317
of 353,904 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#20
of 78 outputs
Altmetric has tracked 25,564,614 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,460 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.7. This one has done well, scoring higher than 79% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 353,904 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 85% of its contemporaries.
We're also able to compare this research output to 78 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.